Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, plcKNSA · Entity 1954 | CHIEF STRATEGY OFFICER | April 07, 2026 | April 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kiniksa Pharmaceuticals International, plc
Report date April 07, 2026 · Filed April 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary ShareSEC Table I · non-derivative | Direct | 23,130 |
Ending reported balance
After 2026-04-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-04-07 · Exercise / conversion · Acquired 2,726 · Balance 23,976 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 2 · 2026-04-07 · Tax withholding · Disposed 846 · Balance 23,130 |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-07 · Exercise / conversion · Disposed 2,726 · Balance 0 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 08, 2024 Filed Apr 8, 2024 21:17 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,726 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-010503 · form4-04082024_090409.xml · derivative · entry 6 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,573 Underlying: Class A Common Share · 2,726 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F6 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. F6 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. Read SEC document |
| April 08, 2024 Filed Apr 8, 2024 21:17 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 801 | $17.90 | $14,337.90 |
DisclosureSEC source: 0001415889-24-010503 · form4-04082024_090409.xml · nonDerivative · entry 2 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,024 Read SEC document |
| April 08, 2024 Filed Apr 8, 2024 21:17 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 2,726 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-010503 · form4-04082024_090409.xml · nonDerivative · entry 1 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,825 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| April 04, 2024 Filed Apr 8, 2024 21:17 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 6,981 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-010503 · form4-04082024_090409.xml · derivative · entry 5 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,299 Underlying: Class A Common Share · 6,981 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F5 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2024, and each yearly anniversary thereafter. F5 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2024, and each yearly anniversary thereafter. Read SEC document |
| April 04, 2024 Filed Apr 8, 2024 21:17 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantPerformance Share Unit · Derivative | 5,585 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-010503 · form4-04082024_090409.xml · derivative · entry 4 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,585 Underlying: Class A Common Share · 5,585 shares Expires 2034-03-31 F3 · derivative.exercise_price: Each Performance Share Unit (PSU) represents a contingent right to receive a number of Class A Common Shares of the Issuer based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee. F4 · derivative.exercise_date: Unless earlier forfeited, each PSU vests and converts into not more than 200% of one Class A Common Share of the Issuer no later than January 30, 2027, unless such date falls on a non-business date, in which case the next business date shall apply. Read SEC document |
| April 04, 2024 Filed Apr 8, 2024 21:17 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 36,300 | $0.00 Strike: $18.06 | $0.00 |
DisclosureSEC source: 0001415889-24-010503 · form4-04082024_090409.xml · derivative · entry 3 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,300 Underlying: Class A Common Share · 36,300 shares Expires 2034-03-31 F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal month installments thereafter. The vesting commencement date is April 1, 2024. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 21:23 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,773 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-010088 · form4-04032024_090445.xml · derivative · entry 3 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,318 Underlying: Class A Common Share · 1,773 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date, April 1, 2023. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date, April 1, 2023. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 21:23 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 521 | $19.70 | $10,263.70 |
DisclosureSEC source: 0001415889-24-010088 · form4-04032024_090445.xml · nonDerivative · entry 2 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,099 Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 21:23 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 1,773 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-010088 · form4-04032024_090445.xml · nonDerivative · entry 1 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,620 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:34 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 656 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001415889-24-006702 · form4-03052024_090322.xml · derivative · entry 3 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,017 Underlying: Class A Common Share · 656 shares Expires 2025-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on March 4, 2022. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:34 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Common Share | 1,189 | $22.03 | $26,193.67 |
DisclosureSEC source: 0001415889-24-006702 · form4-03052024_090322.xml · nonDerivative · entry 2 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 122,847 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on March 4, 2022. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $22.03 and $22.055. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:34 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 656 | $1.59 | $1,043.04 |
DisclosureSEC source: 0001415889-24-006702 · form4-03052024_090322.xml · nonDerivative · entry 1 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,036 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on March 4, 2022. Read SEC document |
| September 02, 2023 Filed Sep 6, 2023 23:04 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,964 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-013040 · form4-09062023_110948.xml · derivative · entry 8 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,928 Underlying: Class A Common Share · 1,964 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F5 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 2, 2021. F5 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 2, 2021. Read SEC document |
| September 02, 2023 Filed Sep 6, 2023 23:04 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 577 | $17.76 | $10,247.52 |
DisclosureSEC source: 0001415889-23-013040 · form4-09062023_110948.xml · nonDerivative · entry 4 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,380 Read SEC document |
| September 02, 2023 Filed Sep 6, 2023 23:04 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 1,964 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-013040 · form4-09062023_110948.xml · nonDerivative · entry 3 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,957 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 23:04 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 42,544 | $0.00 Strike: $17.76 | $0.00 |
DisclosureSEC source: 0001415889-23-013040 · form4-09062023_110948.xml · derivative · entry 7 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,544 Underlying: Class A Common Share · 42,544 shares Expires 2033-08-31 F4 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 23:04 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 7,091 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-013040 · form4-09062023_110948.xml · derivative · entry 6 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,091 Underlying: Class A Common Share · 7,091 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 1, 2023. F3 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 1, 2023. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 23:04 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,727 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-013040 · form4-09062023_110948.xml · derivative · entry 5 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,178 Underlying: Class A Common Share · 2,727 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 1, 2022. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 1, 2022. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 23:04 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 801 | $17.76 | $14,225.76 |
DisclosureSEC source: 0001415889-23-013040 · form4-09062023_110948.xml · nonDerivative · entry 2 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,993 Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 23:04 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 2,727 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-013040 · form4-09062023_110948.xml · nonDerivative · entry 1 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,794 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| April 10, 2023 Filed Apr 11, 2023 21:03 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,727 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-006440 · form4-04112023_090449.xml · derivative · entry 3 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,178 Underlying: Class A Common Share · 2,727 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. Read SEC document |
| April 10, 2023 Filed Apr 11, 2023 21:03 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 801 | $10.71 | $8,578.71 |
DisclosureSEC source: 0001415889-23-006440 · form4-04112023_090449.xml · nonDerivative · entry 2 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,067 Read SEC document |
| April 10, 2023 Filed Apr 11, 2023 21:03 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 2,727 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-006440 · form4-04112023_090449.xml · nonDerivative · entry 1 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,868 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| April 01, 2023 Filed Apr 3, 2023 20:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 7,091 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-005788 · form4-04032023_040410.xml · derivative · entry 2 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,091 Underlying: Class A Common Share · 7,091 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2023. F3 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2023. Read SEC document |
| April 01, 2023 Filed Apr 3, 2023 20:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 42,544 | $0.00 Strike: $10.76 | $0.00 |
DisclosureSEC source: 0001415889-23-005788 · form4-04032023_040410.xml · derivative · entry 1 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,544 Underlying: Class A Common Share · 42,544 shares Expires 2033-03-31 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April1, 2023. Read SEC document |
| March 20, 2023 Filed Mar 20, 2023 21:15 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,982 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-005232 · form4-03202023_090331.xml · derivative · entry 6 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Share · 2,982 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The performance criteria for these RSUs were met. The RSUs vested in a single installment on March 20, 2023; there was no expiration date for the RSUs. F3 · derivative.expiration_date: The performance criteria for these RSUs were met. The RSUs vested in a single installment on March 20, 2023; there was no expiration date for the RSUs. Read SEC document |
| March 20, 2023 Filed Mar 20, 2023 21:15 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 876 | $11.12 | $9,741.12 |
DisclosureSEC source: 0001415889-23-005232 · form4-03202023_090331.xml · nonDerivative · entry 4 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,141 Read SEC document |
| March 20, 2023 Filed Mar 20, 2023 21:15 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 2,982 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-005232 · form4-03202023_090331.xml · nonDerivative · entry 3 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,017 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| March 16, 2023 Filed Mar 20, 2023 21:15 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,964 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-005232 · form4-03202023_090331.xml · derivative · entry 5 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,928 Underlying: Class A Common Share · 1,964 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021. Read SEC document |
| March 16, 2023 Filed Mar 20, 2023 21:15 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 577 | $11.46 | $6,612.42 |
DisclosureSEC source: 0001415889-23-005232 · form4-03202023_090331.xml · nonDerivative · entry 2 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,035 Read SEC document |
| March 16, 2023 Filed Mar 20, 2023 21:15 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 1,964 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-005232 · form4-03202023_090331.xml · nonDerivative · entry 1 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,612 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| September 02, 2022 Filed Sep 6, 2022 20:09 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,964 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-009345 · form4-09062022_010905.xml · derivative · entry 6 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,892 Underlying: Class A Common Share · 1,964 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F5 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021. F5 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021. Read SEC document |
| September 02, 2022 Filed Sep 6, 2022 20:09 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 577 | $11.44 | $6,600.88 |
DisclosureSEC source: 0001415889-22-009345 · form4-09062022_010905.xml · nonDerivative · entry 3 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,648 Read SEC document |
| September 02, 2022 Filed Sep 6, 2022 20:09 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 1,964 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-22-009345 · form4-09062022_010905.xml · nonDerivative · entry 2 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,225 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:09 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 10,905 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-009345 · form4-09062022_010905.xml · derivative · entry 5 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,905 Underlying: Class A Common Share · 10,905 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F4 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. F4 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:09 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 65,420 | $0.00 Strike: $11.97 | $0.00 |
DisclosureSEC source: 0001415889-22-009345 · form4-09062022_010905.xml · derivative · entry 4 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,420 Underlying: Class A Common Share · 65,420 shares Expires 2032-08-31 F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2022. Read SEC document |
| July 15, 2022 Filed Sep 6, 2022 20:09 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantClass A Common Share | 1,048 | $9.56 | $10,018.88 |
DisclosureSEC source: 0001415889-22-009345 · form4-09062022_010905.xml · nonDerivative · entry 1 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,261 F1 · kind: The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of January 16, 2022 to July 15, 2022. The acquisition of such shares was exempt pursuant to Rule 16b-3(c). Read SEC document |
| April 07, 2022 Filed Apr 11, 2022 20:31 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 10,905 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-003992 · form4-04112022_010412.xml · derivative · entry 2 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,905 Underlying: Class A Common Share · 10,905 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. F3 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. Read SEC document |
| April 07, 2022 Filed Apr 11, 2022 20:31 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 65,420 | $0.00 Strike: $11.10 | $0.00 |
DisclosureSEC source: 0001415889-22-003992 · form4-04112022_010412.xml · derivative · entry 1 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,420 Underlying: Class A Common Share · 65,420 shares Expires 2032-04-06 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 7, 2022. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 20:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 4,611 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-003282 · form4-03232022_040302.xml · derivative · entry 3 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Share · 4,611 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The performance criteria for these RSUs were met. The RSUs vested in a single installment on March 20, 2022; there was no expiration date for the RSUs. F2 · derivative.expiration_date: The performance criteria for these RSUs were met. The RSUs vested in a single installment on March 20, 2022; there was no expiration date for the RSUs. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 20:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 1,461 | $10.98 | $16,041.78 |
DisclosureSEC source: 0001415889-22-003282 · form4-03232022_040302.xml · nonDerivative · entry 2 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,213 Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 20:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 4,611 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-22-003282 · form4-03232022_040302.xml · nonDerivative · entry 1 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,674 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:36 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,964 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-002324 · edgar.xml · derivative · entry 5 Tessari Eben · CIK 0001867899 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,892 Underlying: Class A Common Share · 1,964 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F4 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021. F4 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:36 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 681 | $10.13 | $6,898.53 |
DisclosureSEC source: 0001179110-22-002324 · edgar.xml · nonDerivative · entry 4 Tessari Eben · CIK 0001867899 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,063 Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:36 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 1,964 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-22-002324 · edgar.xml · nonDerivative · entry 3 Tessari Eben · CIK 0001867899 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,744 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| January 15, 2022 Filed Mar 18, 2022 20:36 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantClass A Common Share | 970 | $9.63 | $9,341.10 |
DisclosureSEC source: 0001179110-22-002324 · edgar.xml · nonDerivative · entry 2 Tessari Eben · CIK 0001867899 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,780 F2 · kind: The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of July 16, 2021 to January 15, 2022. The acquisition of such shares was exempt pursuant to Rule 16b-3(c). Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 21:21 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 7,856 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-008660 · edgar.xml · derivative · entry 2 Tessari Eben · CIK 0001867899 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,856 Underlying: Class A Common Shares · 7,856 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Share Unit represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The Restricted Share Units (RSUs) vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021. F3 · derivative.expiration_date: The Restricted Share Units (RSUs) vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 21:21 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 47,138 | $0.00 Strike: $12.97 | $0.00 |
DisclosureSEC source: 0001179110-21-008660 · edgar.xml · derivative · entry 1 Tessari Eben · CIK 0001867899 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,138 Underlying: Class A Common Shares · 47,138 shares Expires 2031-09-01 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 2, 2021. Read SEC document |
| July 15, 2021 Filed Mar 18, 2022 20:36 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantClass A Common Share | 868 | $11.49 | $9,973.32 |
DisclosureSEC source: 0001179110-22-002324 · edgar.xml · nonDerivative · entry 1 Tessari Eben · CIK 0001867899 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,810 F1 · kind: The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of January 1, 2021 to July 15, 2021. The acquisition of such shares was exempt pursuant to Rule 16b-3(c). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.